All In Biotech

Drug Trial Radar · NCT06680128

A Study to Assess the Safety, Reactogenicity, and Immunogenicity of SK Japanese Encephalitis Messenger Ribonucleic Acid (mRNA) Vaccines (GBP560) in Healthy Adults

A 2-Stage, Phase I/II, Active-controlled, Randomized, Observer-blinded, Dose-finding Study to Assess the Safety, Reactogenicity, and Immunogenicity of SK Japanese Encephalitis mRNA Vaccines (GBP560) in Healthy Adults (Aged 18 Years and Older)

Last checked: Nov 20, 2026Latest source record: Sep 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 161 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

161

Actual

Start

Feb 24, 2025

Primary completion

Jul 31, 2026

Study completion Jul 31, 2026

Sponsor

Lead sponsor
SK Bioscience Co., Ltd.Industry
Sponsor type
Industry
First posted
Nov 8, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a 2-Stage, Phase I/II Study to Assess the Safety, Reactogenicity, and Immunogenicity of SK Japanese Encephalitis mRNA Vaccines (GBP560) in Healthy Adults (Aged 18 Years and Older)

Conditions

  • Japanese Encephalitis Virus Disease

Interventions

  • GBP560-ABiological

    injection volume of 0.5mililiter (mL) with each dose on V2(1day) and V5 (29day) in stage1 and stage2. Low dose: 3μg Mid dose: 15μg High dose: 50μg

  • GBP560-BBiological

    injection volume of 0.5mL with each dose on V2(1day) and V5 (29day) in stage1 and stage2. Low dose: 3μg Mid dose: 15μg High dose: 50μg

  • IXIAROBiological

    injection volume of 0.5mL on V2(1day) and V5 (29day) in stage1 and stage2

  • IMOJEVBiological

    injection volume of 0.5mL on V5 (29day) in stage1 and stage2

  • Normal Saline (Placebo)Biological

    injection volume of 0.5mL on V2 (1day) in stage1 and stage2 (This is for IMOJEV placebo)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of participants experiencing any immediate reactionsTime frame: 30 minutes (2 hours for the sentinel participants in stage 1) post each vaccination
  2. Percentage of participants reporting any solicited local Adverse Event (AE)Time frame: during the 7 days following each study vaccination
  3. Percentage of participants reporting any solicited systemic Adverse Event (AE)Time frame: during the 7 days following each study vaccination
  4. Percentage of participants experiencing any unsolicited Adverse Event (AE)Time frame: during the 28 days following each study vaccination
  5. Percentage of participants with any Medically Attended Adverse Event (MAAE)Time frame: until 6 months following the last study vaccination
  6. Percentage of participants experiencing any Adverse Event of Special Interest (AESI)s, AEs leading to study withdrawal and Serious Adverse Event (SAE)s during the entire study periodTime frame: up to 12 months for stage 1 and up to 24 months for stage 2
  7. Seroprotection rate for both the respective and cross Japanese encephalitis virus (JEV) strains of each vaccine (SA14-14-2 and Beijing-1 strain) in live-virus neutralizing antibody titers at each time pointTime frame: At baseline, 2 weeks, 4 weeks following the 1st study vaccination, and at 2 weeks, 4 weeks, 3 months, 6 months, 12 months, and 24 months following the 2nd study vaccination.
  8. Seroresponse rate for both the respective and cross JEV strains of each vaccine (SA14-14-2 and Beijing-1 strain) in live-virus neutralizing antibody titers, from baseline to each subsequent time pointTime frame: At baseline, 2 weeks, 4 weeks following the 1st study vaccination, and at 2 weeks, 4 weeks, 3 months, 6 months, 12 months, and 24 months following the 2nd study vaccination
  9. Geometric Mean Titer (GMT) of neutralizing antibody against both the respective and cross JEV strains of each vaccine (SA14-14-2 and Beijing-1 strain) measured by a live-virus neutralization assay (PRNT) at each time pointTime frame: At baseline, 2 weeks, 4 weeks following the 1st study vaccination, and at 2 weeks, 4 weeks, 3 months, 6 months, 12 months, and 24 months following the 2nd study vaccination.
  10. Geometric mean fold rise of neutralizing antibody against both the respective and cross JEV strains of each vaccine (SA14-14-2,Beijing-1 strain), measured by a live-virus neutralization assay(PRNT), from each pre-vaccination to each subsequent timepointTime frame: At baseline, 2 weeks, 4 weeks following the 1st study vaccination, and at 2 weeks, 4 weeks, 3 months, 6 months, 12 months, and 24 months following the 2nd study vaccination
  11. Geometric mean fold reduction of neutralizing antibody against both respective and cross JEV strains of each vaccine (SA-14-14-2,Beijing-1 strain), measured by live-virus neutralization assay (PRNT) from persistence baseline to each subsequent timepointTime frame: At baseline, 2 weeks, 4 weeks following the 1st study vaccination, and at 2 weeks, 4 weeks, 3 months, 6 months, 12 months, and 24 months following the 2nd study vaccination.

Locations

3 sites in 2 countries. Site status is shown where the registry gives one.

  • Nucleus Network - Brisbane (Q Pharm)

    Brisbane, Australia

  • Nucleus Network - Melbourne

    Melbourne, Australia

  • New Zealand Clinical Research

    Christchurch, Central City, New Zealand

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.